ClinVar Miner

Submissions for variant NM_000527.5(LDLR):c.1124A>G (p.Tyr375Cys)

dbSNP: rs879254800
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
LDLR-LOVD, British Heart Foundation RCV000237921 SCV000295235 likely pathogenic Hypercholesterolemia, familial, 1 2016-03-25 criteria provided, single submitter literature only
Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies, APHP, GH Hôpitaux Universitaires Pitié-Salpêtrière / Charles-Foix RCV000237921 SCV000503302 likely pathogenic Hypercholesterolemia, familial, 1 2016-12-16 criteria provided, single submitter clinical testing subjects mutated among 2600 FH index cases screened = 3 , family members = 4 with co-segregation / previously described in association with FH / Software predictions: Damaging
U4M - Lille University & CHRU Lille, Université de Lille - CHRU de Lille RCV000237921 SCV000583792 pathogenic Hypercholesterolemia, familial, 1 2017-03-30 criteria provided, single submitter clinical testing
Fundacion Hipercolesterolemia Familiar RCV000237921 SCV000607561 likely pathogenic Hypercholesterolemia, familial, 1 2016-03-01 criteria provided, single submitter research
Fulgent Genetics, Fulgent Genetics RCV000237921 SCV000894173 pathogenic Hypercholesterolemia, familial, 1 2018-10-31 criteria provided, single submitter clinical testing
Invitae RCV001063149 SCV001227983 pathogenic Familial hypercholesterolemia 2023-09-13 criteria provided, single submitter clinical testing ClinVar contains an entry for this variant (Variation ID: 251679). For these reasons, this variant has been classified as Pathogenic. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt LDLR protein function. This variant is also known as Y354C. This missense change has been observed in individuals with familial hypercholesterolemia (PMID: 9195230, 11668640, 15823288). It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 375 of the LDLR protein (p.Tyr375Cys).
Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, Montreal Heart Institute RCV000237921 SCV001433510 likely pathogenic Hypercholesterolemia, familial, 1 2019-09-05 criteria provided, single submitter clinical testing
Ambry Genetics RCV002436076 SCV002746153 pathogenic Cardiovascular phenotype 2018-02-23 criteria provided, single submitter clinical testing The p.Y375C pathogenic mutation (also known as c.1124A>G), located in coding exon 8 of the LDLR gene, results from an A to G substitution at nucleotide position 1124. The tyrosine at codon 375, in the cbEGF-like #2, is replaced by cysteine, an amino acid with highly dissimilar properties. This alteration, referred to as Y354C, was reported in a pediatric French-Canadian proband with familial hypercholesterolemia (FH), and also segregated with the disease in the family. In addition, reduced LDLR activity was revealed in the proband's fibroblasts (Assouline L et al. Hum. Mutat., 1997;9:555-62). This alteration was also reported in association with FH in other populations (Chaves FJ et al. J. Clin. Endocrinol. Metab., 2001 Oct;86:4926-32; Damgaard D et al. Atherosclerosis, 2005 May;180:155-60). Moreover, an alteration affecting the same amino acid, Y375S, was also described in a child with FH and her affected mother (Mollaki V et al. Ann. Hum. Genet., 2013 Sep;77:426-34). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
PreventionGenetics, part of Exact Sciences RCV003391007 SCV004119970 pathogenic LDLR-related condition 2023-03-31 criteria provided, single submitter clinical testing The LDLR c.1124A>G variant is predicted to result in the amino acid substitution p.Tyr375Cys. This variant is also described using legacy nomenclature as p.Tyr354Cys, has been reported to be causative for familial hypercholesterolemia (FH) in multiple individuals (Assouline et al. 1997. PubMed ID: 9195230; García-García et al. 2001. PubMed ID: 11668640; Damgaard et al. 2005. PubMed ID: 15823288). A similar variant, c.1124A>C (p.Tyr375Ser) has also been reported in individuals with FH (Mollaki et al. 2013. PubMed ID: 23815734) suggesting that amino acid residue p.Tyr375 is important for proper LDLR protein function. This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. This variant is interpreted as pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.